Impact of hepatitis B immunoglobulin mode of administration on treatment experiences of patients after liver transplantation: Results from an online survey

Figure 1 Current hepatitis B immunoglobulin treatment. A: Life aspects affected; B: Patient experience. ^aP ≤ 0.05 denotes statistically significant difference vs intravenous hepatitis B immunoglobulin. ¹Issues caused by treatment. HBIG: Hepatitis B immunoglobulin; IM: Intramuscular; IV: Intravenous; SC: Subcutaneous.

Figure 2 Challenges faced by patients using hepatitis B immunoglobulin treatment. ^aP ≤ 0.05 denotes statistically significant difference vs intravenous hepatitis B immunoglobulin. HBIG: Hepatitis B immunoglobulin; IM: Intramuscular; IV: Intravenous; SC: Subcutaneous.

Figure 3 Satisfaction with current hepatitis B immunoglobulin treatment. Percentages are rounded to the nearest whole numbers therefore may not add up to 100% for each column. ^aP ≤ 0.05 denotes statistically significant difference vs intravenous hepatitis B immunoglobulin. ¹Percentages calculated as a proportion of 89 patients who responded to this question. ²Percentages calculated as a proportion of 45 patients who responded to this question. HBIG: Hepatitis B immunoglobulin; IM: Intramuscular; IV: Intravenous; SC: Subcutaneous.

Figure 4 Factors influencing choice of most appropriate hepatitis B immunoglobulin treatment. ^aP ≤ 0.05 denotes statistically significant difference vs intravenous hepatitis B immunoglobulin. HBIG: Hepatitis B immunoglobulin; IM: Intramuscular; IV: Intravenous; SC: Subcutaneous.

Figure 5 Statements describing patients’ perceptions of ‘convenience’ regarding hepatitis B immunoglobulin treatments. Percentages refer to the proportion of patients who, unprompted, mentioned the specific aspects listed. HBIG: Hepatitis B immunoglobulin; IM: Intramuscular; IV: Intravenous; SC: Subcutaneous.